Liu Chao, Wang Jinghui, Yiu Daofeng, Liu Kunshen
The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China; Department of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Cardiovasc Ther. 2014 Jun;32(3):89-96. doi: 10.1111/1755-5922.12062.
cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in preventing POAF, or length of intensive care unite (ICU) or hospital stay.
A systematic electronic database literature search of Cochrane controlled trials register (2013, issue 4) and MEDLINE (1966 to April, 2013) was conducted using specific search terms for all relevant articles. Including criteria were: randomized controlled clinical trials, participants were adults (≥18 years of age) undergoing cardiac surgery, evaluated glucocorticoid prophylaxis in cardiac surgery with adequately reported data on incidence of POAF, or length of ICU or hospital stay.
Forty-two randomized controlled trials involving 7621 participants were included in the meta-analysis. Overall, glucocorticoids prophylaxis significantly lowered participants' risk of developing POAF (Relative Risk [RR] 0.77; 95% confidence interval [CI] 0.66-0.90), P < 0.01), reduced length of ICU stay by 0.25 day (95% CI -0.40 to -0.10, P < 0.01). Glucocorticoid prophylaxis in cardiac surgery was not associated with increased all-cause of infection (RR 0.68; 95% CI 0.58-0.78, P < 0.01) and mortality (RR 0.75; 95% CI 0.52-1.08, P = 0.12).
Pooled evidence suggests that glucocorticoid prophylaxis may reduce the incidence of POAF. The beneficial effect on POAF is associated with reduced length of ICU and hospital stay, and infection rate.
体外循环和心脏手术会引发显著的全身炎症反应,有人认为这种反应在围手术期房颤(POAF)的发生发展中起因果作用。本荟萃分析的目的是确定糖皮质激素预防在预防POAF、缩短重症监护病房(ICU)住院时间或医院住院时间方面的疗效。
使用特定搜索词对Cochrane对照试验注册库(2013年第4期)和MEDLINE(1966年至2013年4月)进行系统的电子数据库文献检索,以查找所有相关文章。纳入标准为:随机对照临床试验,参与者为接受心脏手术的成年人(≥18岁),评估心脏手术中糖皮质激素预防情况,且有关于POAF发生率或ICU或医院住院时间的充分报告数据。
荟萃分析纳入了42项涉及7621名参与者的随机对照试验。总体而言,糖皮质激素预防显著降低了参与者发生POAF的风险(相对风险[RR]0.77;95%置信区间[CI]0.66 - 0.90,P < 0.01),将ICU住院时间缩短了0.25天(95%CI -0.40至-0.10,P < 0.01)。心脏手术中糖皮质激素预防与全因感染增加(RR 0.68;95%CI 0.58 - 0.78,P < 0.01)和死亡率增加(RR 0.75;95%CI 0.52 - 1.08,P = 0.12)无关。
汇总证据表明,糖皮质激素预防可能降低POAF的发生率。对POAF的有益作用与缩短ICU和医院住院时间以及感染率降低有关。